Youmanitarian 12 Jun 2021

Volgende

Automatisch afspelen

Understand Cancer & Reduce Cancer Risk | Dr. Peter Attia & Dr. Andrew Huberman

uchetex · 12 Bekeken

Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor

0

0

14 Bekeken

TAKE ACTION

Donations would go to support charities for How-To & Style

In How-To & Style

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Laat meer zien

More ways to take action

Explore ways that you can help bring a solution to this issue.

Create Youms with
hashtags How-To & Style

Create a challenge to
bring awareness to this issue for people to complete

Create a fundraiser to
support a charity that tackle this issue

Volunteer at charitable organization
that support this cause

Create a movement page dedicated to this cause to bring awareness.

Start a uCharity for this cause and invite people to join it to support this cause

Volgende

Automatisch afspelen

Understand Cancer & Reduce Cancer Risk | Dr. Peter Attia & Dr. Andrew Huberman

uchetex · 12 Bekeken

Huis

Categorieën